Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod

Given the requirement for patients to have a Ki-67 score of at least 20%, the challenge now is to alter physicians’ thinking around Ki-67 testing, execs told Scrip.

Doctor with Mammography - Image
The FDA approved Lilly's Verzenio for certain early-stage HR+/HER2- breast cancer patients • Source: Shutterstock

More from New Products

More from Scrip